CLDI — what changed in the latest 10-Q
A section-by-section comparison of CLDI's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +25 | −30 | ~19 | 67 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
● Deliver genetic medicine payloads for expression in the TME like IL-15 superagonist (CLD-401), coexpression of in situ T-cell engagers (TCEs) and T-cell activators as in CLD-501 (anti-TROP2) and CLD-502 (anti-EpCAM), to combine oncolytic tumor killing, TME remodeling, and T-cell redirection agains…
On June 12, 2026, our stockholders approved an amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to, at the discretion of the Board of Directors, to effect a reverse stock split with respect to our shares of issued and outstanding Common Stock, which consists of …
On May 6, 2026, we issued a warrant (“Warrant”) to an accredited investor to purchase up to 1,086,957 unvested shares of our common stock (“Common Stock”) with an exercise price of $3.68 in a private placement transaction. The Warrant is exercisable beginning on the date that is six months from the …
On May 28, 2026, we amended and restated the Warrant to among other things: (i) condition the exercise of the Warrant and the issuance of the Common Stock upon exercise pursuant to the terms of the Warrant, to the receipt of the approval of our stockholders; (ii) increase the Minimum Vesting Acquisi…
On July 10, 2026, we entered into a new lease agreement (the “New Lease”) for approximately 9,038 rentable square feet of office and laboratory space located at 5580 Morehouse Drive, Suite 120, San Diego, California, with an initial term of 44 months commencing October 1, 2026, and expiring May 31, …
Text removed vs the prior filing · source: 10-Q · 2026-05-14
● Deliver genetic medicine payloads like IL-15 superagonist for expression in the TME.
On March 5, 2026, we entered into an Amendment to Common Stock Purchase Warrants Agreement (the “Warrant Amendment”) with certain investors that participated in the March Confidentially Marketed Public Offering described below, in connection with the terms of certain of our outstanding common warran…
- 504,417 shares of common stock, on exercise of the Series G common stock warrants at an exercise price of $8.3448 per share;
- 279,168 shares of common stock, on exercise of the Series H common stock warrants at an exercise price of $8.40 per share; and
- 2,190,000 shares of common stock, on exercise of the Series I common stock warrants at an exercise price of $2.00 per share.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice